Last reviewed · How we verify
Rosuvastatin calcium 40mg
Rosuvastatin calcium 40mg, marketed by Seung-Jung Park, is a leading statin in its class with a strong market presence. The key composition patent expires in 2028, providing a significant period of exclusivity and competitive advantage. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Rosuvastatin calcium 40mg |
|---|---|
| Also known as | CRESTOR® 40mg, Crestor, Intensified Statin Therapy, Experimental active drug, Ezetimib 10mg |
| Sponsor | Seung-Jung Park |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (PHASE1)
- [Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers] (PHASE1)
- Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers (PHASE1)
- Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial) (PHASE4)
- Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial (NA)
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (PHASE1)
- Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin calcium 40mg CI brief — competitive landscape report
- Rosuvastatin calcium 40mg updates RSS · CI watch RSS
- Seung-Jung Park portfolio CI